Article info
PDFBenefits to participants
Paper
An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research
- Correspondence to Dr David Evans, 705 El Centro Street, South Pasadena, CA 91030, USA; devans{at}projectinform.org
Citation
An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research
Publication history
- Received January 29, 2016
- Revised December 1, 2016
- Accepted December 2, 2016
- First published January 6, 2017.
Online issue publication
January 25, 2017
Article Versions
- Previous version (25 January 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Other content recommended for you
- For love and money: the need to rethink benefits in HIV cure studies
- Cure research and consent: the Mississippi Baby, Barney Clark, Baby Fae and Martin Delaney
- Why cure, why now?
- Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?
- How to keep high-risk studies ethical: classifying candidate solutions
- Reconceptualising risk–benefit analyses: the case of HIV cure research
- Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity
- Factors associated with attitudes towards HIV cure research among transgender women and travestis: a cross-sectional survey in São Paulo, Brazil
- Informed consent to HIV cure research
- Improving on effective antiretroviral therapy: how good will a cure have to be?